Stock CZO CEAPRO INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Ceapro Inc.

Equities

CZO

CA1499071076

Biotechnology & Medical Research

Market Closed - Toronto S.E.
Other stock markets
 03:08:52 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.26 CAD +8.33% Intraday chart for Ceapro Inc. +6.12% +36.84%
Mar. 28 Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions MT
Mar. 28 Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris MT

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 37.77 29.66 24.75 51.23 47.39 46.16
Enterprise Value (EV) 1 33.13 28.45 26.18 48.83 42.26 34.97
P/E ratio -38.5 x -93 x -21.8 x 33 x 16.7 x 10.5 x
Yield - - - - - -
Capitalization / Revenue 2.92 x 2.56 x 1.92 x 3.39 x 2.76 x 2.45 x
EV / Revenue 2.56 x 2.45 x 2.03 x 3.23 x 2.46 x 1.86 x
EV / EBITDA 13.1 x 110 x 22.6 x 13.1 x 10.6 x 5.48 x
EV / FCF -50.2 x -6.76 x 18.1 x 15.1 x 22.3 x 10.8 x
FCF Yield -1.99% -14.8% 5.53% 6.64% 4.49% 9.22%
Price to Book 1.68 x 1.28 x 1.11 x 2.11 x 1.74 x 1.43 x
Nbr of stocks (in thousands) 75,547 77,045 77,336 77,621 77,686 78,233
Reference price 2 0.5000 0.3850 0.3200 0.6600 0.6100 0.5900
Announcement Date 4/20/18 4/11/19 4/16/20 4/22/21 4/13/22 4/12/23
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 12.93 11.59 12.88 15.12 17.2 18.84
EBITDA 1 2.537 0.2586 1.159 3.724 3.985 6.38
EBIT 1 2.213 -0.3068 -0.326 2.347 2.623 5.499
Operating Margin 17.12% -2.65% -2.53% 15.52% 15.26% 29.19%
Earnings before Tax (EBT) 1 -0.4268 -0.9212 -1.136 1.856 2.619 5.777
Net income 1 -0.9583 -0.3155 -1.133 1.856 2.842 4.398
Net margin -7.41% -2.72% -8.79% 12.27% 16.53% 23.34%
EPS 2 -0.0130 -0.004140 -0.0147 0.0200 0.0366 0.0564
Free Cash Flow 1 -0.66 -4.207 1.447 3.24 1.898 3.225
FCF margin -5.11% -36.29% 11.24% 21.43% 11.04% 17.12%
FCF Conversion (EBITDA) - - 124.94% 87.01% 47.62% 50.54%
FCF Conversion (Net income) - - - 174.57% 66.76% 73.32%
Dividend per Share - - - - - -
Announcement Date 4/20/18 4/11/19 4/16/20 4/22/21 4/13/22 4/12/23
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - 1.43 - - -
Net Cash position 1 4.65 1.21 - 2.4 5.13 11.2
Leverage (Debt/EBITDA) - - 1.234 x - - -
Free Cash Flow 1 -0.66 -4.21 1.45 3.24 1.9 3.22
ROE (net income / shareholders' equity) -4.26% -1.38% -4.98% 7.96% 11% 14.7%
ROA (Net income/ Total Assets) 5.1% -0.72% -0.77% 5.19% 5.49% 9.99%
Assets 1 -18.77 43.72 146.2 35.75 51.79 44.01
Book Value Per Share 2 0.3000 0.3000 0.2900 0.3100 0.3500 0.4100
Cash Flow per Share 2 0.0800 0.0200 0.0200 0.0700 0.1000 0.1800
Capex 1 4.02 1.26 0.34 0.62 0.71 0.34
Capex / Sales 31.09% 10.83% 2.63% 4.09% 4.12% 1.81%
Announcement Date 4/20/18 4/11/19 4/16/20 4/22/21 4/13/22 4/12/23
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CEAPRO INC. Stock Ceapro Inc.
+36.84% 14.87M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+48.54% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CZO Stock
  4. Financials Ceapro Inc.